Among various types of anti-diabetic drugs, recent clinical trials have demonstrated the beneficial effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors in reducing the risk of atherosclerotic cardiovascular disease (ASCVD) in addition to improvements in HbA1c.2 Here, SLC5A2 is linked to atherosclerosis.